

From Sequence Design to AOC Production: Medicilon’s End-to-End RNAi Development Platform




Ao Huang¹, Lei Qian¹, Maosheng Du¹, Bin Yan¹, Zhengyu Long¹, Qingcong Lin¹ and Steven Zhang²

¹ Shanghai Medicilon Inc., 585 Chuanda Road, Shanghai 201299, China; ² Medicilon-USA Corp., 20 Maguire Road, Suite 103, Lexington, MA 02421, USA.

Anchored by a sophisticated RNAi platform, our AOC capabilities are supported by advanced conjugation chemistries and high-resolution analytical methodologies, and enabled by integrated expertise spanning sequence design, nucleotide synthesis, and in vivo evaluation, together providing a one-stop solution for next-generation oligonucleotide therapeutics.

Medicilon Optimal Design (MOD)

Mono-Nucleotide Synthesis



Delivery & Carrier Synthesis